Education
About Us
Working with TipRanks
Follow Us
Agios Pharmaceuticals (AGIO)
NASDAQ:AGIO
AGIO Stock Chart & Stats
$27.19
-$0.03(-0.09%)
At close: 4:00 PM EST
$27.19
-$0.03(-0.09%)
Day’s Range― - ―
52-Week Range$22.24 - $46.00
Previous CloseN/A
Volume212.48K
Average Volume (3M)1.33M
Market Cap
$1.62B
Enterprise Value$1.43B
Total Cash (Recent Filing)$952.86M
Total Debt (Recent Filing)$44.52M
Price to Earnings (P/E)―
Beta2.00
Next Earnings
Feb 12, 2026EPS Estimate
-1.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.78
Shares Outstanding58,313,812
10 Day Avg. Volume964,723
30 Day Avg. Volume1,329,764
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.21
Price to Sales (P/S)51.14
P/FCF Ratio-4.77
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue31.82
Enterprise Value/Gross Profit37.70
Enterprise Value/Ebitda-3.23
Forecast
1Y Price Target
$36.14Price Target Upside32.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-6.65
Revenue Forecast (FY)$97.52M
Bulls Say, Bears Say
Bulls Say
Commercial Adoption PotentialHigh physician enthusiasm and intent to prescribe, combined with a launch strategy targeting patients with the largest transfusion burden, supports concentrated early uptake and revenue generation.
Market Opportunity And PricingPremium pricing aligned with clinician-perceived value positions Aqvesme to capture a sizable market opportunity that could materially contribute to company revenue if adoption scales as expected.
Regulatory ApprovalFDA approval of Aqvesme for both transfusion-dependent and non-transfusion-dependent alpha- and beta-thalassemia expands the treatable patient population and establishes the drug as an oral therapy across transfusion burdens.
Bears Say
Launch Execution RiskComplexities of the thalassemia patient population and REMS logistics are likely to produce a gradual, specialist-centered launch that could delay broader commercial uptake.
Regulatory And Indication UncertaintyA more complicated path to market in sickle cell disease, together with regulatory extensions tied to REMS discussions, creates uncertainty around future label expansion and longer-term revenue upside.
REMS And Safety MonitoringA REMS requiring frequent liver tests and a black box warning increases administrative burden for prescribers and may restrict patient access through added monitoring requirements.
Agios Pharma News
AGIO FAQ
What was Agios Pharmaceuticals’s price range in the past 12 months?
Agios Pharmaceuticals lowest stock price was $22.24 and its highest was $46.00 in the past 12 months.
What is Agios Pharmaceuticals’s market cap?
Agios Pharmaceuticals’s market cap is $1.62B.
When is Agios Pharmaceuticals’s upcoming earnings report date?
Agios Pharmaceuticals’s upcoming earnings report date is Feb 12, 2026 which is in 24 days.
How were Agios Pharmaceuticals’s earnings last quarter?
Agios Pharmaceuticals released its earnings results on Oct 30, 2025. The company reported -$1.78 earnings per share for the quarter, beating the consensus estimate of -$1.897 by $0.117.
Is Agios Pharmaceuticals overvalued?
According to Wall Street analysts Agios Pharmaceuticals’s price is currently Undervalued.
Does Agios Pharmaceuticals pay dividends?
Agios Pharmaceuticals does not currently pay dividends.
What is Agios Pharmaceuticals’s EPS estimate?
Agios Pharmaceuticals’s EPS estimate is -1.95.
How many shares outstanding does Agios Pharmaceuticals have?
Agios Pharmaceuticals has 58,313,812 shares outstanding.
What happened to Agios Pharmaceuticals’s price movement after its last earnings report?
Agios Pharmaceuticals reported an EPS of -$1.78 in its last earnings report, beating expectations of -$1.897. Following the earnings report the stock price went up 2.908%.
Which hedge fund is a major shareholder of Agios Pharmaceuticals?
Currently, no hedge funds are holding shares in AGIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agios Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$36.14 (32.92% Upside)
$36.14 (32.92% Upside)
Blogger Sentiment
Bullish
AGIO Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 183.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 11.3%
Last 30 Days ▲ 11.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.55%
12-Months-Change
Fundamentals
Return on Equity
-27.57%
Trailing 12-Months
Asset Growth
-22.66%
Trailing 12-Months
Company Description
Agios Pharmaceuticals
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
AGIO Company Deck
AGIO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with strong financial performance, global regulatory progress, and significant pipeline advancements. However, there are challenges with increased expenses and potential regulatory hurdles related to the REMS program.View all AGIO earnings summariesAGIO Stock 12 Month Forecast
Average Price Target
$36.14
▲(32.92% Upside)
Technical Analysis
ImmunityBio
―
Denali Therapeutics
―
NewAmsterdam Pharma Company
―
Recursion Pharmaceuticals
―
Apogee Therapeutics
―
Ownership Overview
Currently, No data available
---